Thalidomide inhibition of vascular remodeling and inflammatory reactivity in the quinolinic acid-injected rat striatum

Neuroscience

Volumn 163, Issue 2, 2009, Pages 601-608

  Ryu, J K ^a   Jantaratnotai, N ^b   McLarnon, J G ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b Mahidol University ^*  (Thailand)

Author keywords

excitotoxicity; microgliosis; quinolinic acid; thalidomide; vascular remodeling

Indexed keywords

BIOLOGICAL MARKER; COLLAGEN TYPE 4; ED1 PROTEIN; GLIAL FIBRILLARY ACIDIC PROTEIN; LAMININ; QUINOLINIC ACID; THALIDOMIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ASTROCYTOSIS; BRAIN BLOOD VESSEL; CELL VIABILITY; CONTROLLED STUDY; CORPUS STRIATUM; EXCITOTOXICITY; GLIOSIS; INFLAMMATION; MALE; NEOVASCULARIZATION (PATHOLOGY); NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; RAT;

ANGIOGENESIS INHIBITORS; ANIMALS; ASTROCYTES; BLOOD VESSELS; CELL SURVIVAL; CORPUS STRIATUM; GLIOSIS; MALE; MICROGLIA; NEOVASCULARIZATION, PATHOLOGIC; NEURONS; NEUROTOXINS; QUINOLINIC ACID; RATS; RATS, SPRAGUE-DAWLEY; THALIDOMIDE; TIME FACTORS;

EID: 69249206617     PISSN: 03064522     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2009.07.006     Document Type: Article

References (32)

1. Bal-Price A., and Brown G.C. Inflammatory neurodegeneration mediated by nitric oxide from activated glia-inhibiting neuronal respiration, causing glutamate release and excitotoxicity. J Neurosci 21 (2001) 6480-6491
2. Contino-Pepin C., Parat A., Perino S., Lenoir C., Vidal M., Galons H., Karlik S., and Pucci B. Preliminary biological evaluations of new thalidomide analogues for multiple sclerosis application. Bioorg Med Chem Lett 19 (2009) 878-881
3. D'Amato R.J., Loughnan M.S., Flynn E., and Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci U S A 91 (1994) 4082-4085
4. de la Torre J.C. Alzheimer disease as a vascular disorder: nosological evidence. Stroke 33 (2002) 1152-1162
5. Dimopoulos M.A., and Eleutherakis-Papaiakovou V. Adverse effects of thalidomide administration in patients with neoplastic diseases. Am J Med 117 (2004) 508-515
6. Franciosi S., De Gasperi R., Dickstein D.L., English D.F., Rocher A.B., Janssen W.G., Christoffel D., Sosa M.A., Hof P.R., Buxbaum J.D., and Elder G.A. Pepsin pretreatment allows collagen IV immunostaining of blood vessels in adult mouse brain. J Neurosci Methods 163 (2007) 76-82
7. Grover J.K., Uppal G., and Raina V. The adverse effects of thalidomide in relapsed and refractory patients of multiple myeloma. Ann Oncol 13 (2002) 1636-1640
8. Hales B.F. Thalidomide on the comeback trail. Nat Med 5 (1999) 489-490
9. Ientile R., Macaione V., Teletta M., Pedale S., Torre V., and Macaione S. Apoptosis and necrosis occurring in excitotoxic cell death in isolated chick embryo retina. J Neurochem 79 (2001) 71-78
10. Kaicker S., McCrudden K.W., Beck L., New T., Huang J., Frischer J.S., Serur A., Kadenhe-Chiweshe A., Yokoi A., Kandel J.J., and Yamashiro D.J. Thalidomide is anti-angiogenic in a xenograft model of neuroblastoma. Int J Oncol 23 (2003) 1651-1655
11. Kalaria R.N., Cohen D.L., Premkumar D.R., Nag S., LaManna J.C., and Lust W.D. Vascular endothelial growth factor in Alzheimer's disease and experimental cerebral ischemia. Brain Res Mol Brain Res 62 (1998) 101-105
12. Kenyon B.M., Browne F., and D'Amato R.J. Effects of thalidomide and related metabolites in a mouse corneal model of neovascularization. Exp Eye Res 64 (1997) 971-978
13. Kim G.W., Copin J.C., Kawase M., Chen S.F., Sato S., Gobbel G.T., and Chan P.H. Excitotoxicity is required for induction of oxidative stress and apoptosis in mouse striatum by the mitochondrial toxin, 3-nitropropionic acid. J Cereb Blood Flow Metab 20 (2000) 119-129
14. Krum J.M., and Khaibullina A. Inhibition of endogenous VEGF impedes revascularization and astroglial proliferation: roles for VEGF in brain repair. Exp Neurol 181 (2003) 241-257
15. Lehrmann E., Molinari A., Speciale C., and Schwarcz R. Immunohistochemical visualization of newly formed quinolinate in the normal and excitotoxically lesioned rat striatum. Exp Brain Res 141 (2001) 389-397
16. Madhusudan S., and Harris A.L. Drug inhibition of angiogenesis. Curr Opin Pharmacol 2 (2002) 403-414
17. Mattson M.P. Excitotoxic and excitoprotective mechanisms: abundant targets for the prevention and treatment of neurodegenerative disorders. Neuromol Med 3 (2003) 65-94
18. Moreira A.L., Sampaio E.P., Zmuidzinas A., Frindt P., Smith K.A., and Kaplan G. Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation. J Exp Med 177 (1993) 1675-1680
19. Mori S., Sternberger N.H., Herman M.M., and Sternberger L.A. Variability of laminin immunoreactivity in human autopsy brain. Histochemistry 97 (1992) 237-241
20. Paxinos G., and Watson C. The rat brain in stereotaxic coordinates. 2nd ed. (1986), Academic Press, New York, NY
21. Pearson V.L., Rothwell N.J., and Toulmond S. Excitotoxic brain damage in the rat induces interleukin-1beta protein in microglia and astrocytes: correlation with the progression of cell death. Glia 25 (1999) 311-323
22. Peterson P.K., Hu S., Sheng W.S., Kravitz F.H., Molitor T.W., Chatterjee D., and Chao C.C. Thalidomide inhibits tumor necrosis factor-alpha production by lipopolysaccharide- and lipoarabinomannan-stimulated human microglial cells. J Infect Dis 172 (1995) 1137-1140
23. Rajkumar S.V., and Witzig T.E. A review of angiogenesis and antiangiogenic therapy with thalidomide in multiple myeloma. Cancer Treat Rev 26 (2000) 351-362
24. Rosenstein J.M., Mani N., Silverman W.F., and Krum J.M. Patterns of brain angiogenesis after vascular endothelial growth factor administration in vitro and in vivo. Proc Natl Acad Sci U S A 95 (1998) 7086-7091
25. Ryu J.K., and McLarnon J.G. VEGF receptor antagonist cyclo-VEGI reduces inflammatory reactivity and vascular leakiness and is neuroprotective against acute excitotoxic striatal insult. J Neuroinflammation 5 (2008) 18
26. Ryu J.K., and McLarnon J.G. Thalidomide inhibition of perturbed vasculature and glial-derived tumor necrosis factor-alpha in an animal model of inflamed Alzheimer's disease brain. Neurobiol Dis 29 (2008) 254-266
27. Ryu J.K., Kim S.U., and McLarnon J.G. Blockade of quinolinic acid-induced neurotoxicity by pyruvate is associated with inhibition of glial activation in a model of Huntington's disease. Exp Neurol 187 (2004) 150-159
28. Ryu J.K., Choi H.B., and McLarnon J.G. Peripheral benzodiazepine receptor ligand PK11195 reduces microglial activation and neuronal death in quinolinic acid-injected rat striatum. Neurobiol Dis 20 (2005) 550-561
29. Santamaria A., Salvatierra-Sanchez R., Vazquez-Roman B., Santiago-Lopez D., Villeda-Hernandez J., Galvan-Arzate S., Jimenez-Capdeville M.E., and Ali S.F. Protective effects of the antioxidant selenium on quinolinic acid-induced neurotoxicity in rats: in vitro and in vivo studies. J Neurochem 86 (2003) 479-488
30. Siao C.J., and Tsirka S.E. Tissue plasminogen activator mediates microglial activation via its finger domain through annexin II. J Neurosci 22 (2002) 3352-3358
31. Szabo A., and Kalman M. Disappearance of the post-lesional laminin immunopositivity of brain vessels is parallel with the formation of gliovascular junctions and common basal lamina. A double-labelling immunohistochemical study. Neuropathol Appl Neurobiol 30 (2004) 169-177
32. Teo S.K., Resztak K.E., Scheffler M.A., Kook K.A., Zeldis J.B., Stirling D.I., and Thomas S.D. Thalidomide in the treatment of leprosy. Microbes Infect 4 (2002) 1193-1202